This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Pifeltro
  • /
  • Safety and Efficacy of Doravirine (MK-1439) in Par...
Clinical trial

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Read time: 3 mins
Last updated:1st Dec 2014
Identifier: NCT02275780

Brief Summary:
To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 769 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects
Actual Study Start Date: December 1, 2014
Actual Primary Completion Date: September 29, 2016
Estimated Study Completion Date: June 23, 2021

Arm:
- Experimental:
Doravirine 100 mg
- Active Comparator: Darunavir 800 mg and Ritonavir 100 mg

Category Value
Date last updated at source 2018-10-23
Study type(s) Interventional
Expected enrolment 769
Study start date 2014-12-01
Estimated primary completion date 2016-09-29

View full details